CYBN חוב כולל להון Cybin

Cybin Inc. (CYBN) is a biotech innovator whose pricing power is based on patents for unique depression therapy formulas. Stable management under Doug Drisdale is confidently steering key programs toward completion, backed by major funds. This price chart on GURU.Markets shows that the debt-to-equity ratio is 0.22, while a diversified portfolio of small molecules minimizes FDA approval risks.

Cybin Inc. is currently in a phase of intensive development of innovative psilocybin-based drugs. The ratio is calculated as the sum of all liabilities divided by the company's net assets. This metric determines the extent to which the biotech pipeline's development depends on external borrowings relative to equity. Excessive leverage increases the risk of default, whereas a lack thereof may slow the pace of research. By analyzing the balance between debt and equity, an investor assesses the financial stability of the company.